Hormonal
CJC-1295 (DAC)
Long-Acting GHRH Analog
Scientific Overview
CJC-1295 is a long-acting growth hormone–releasing hormone (GHRH) analog designed for prolonged GH and IGF-1 elevation via albumin binding (DAC versions).
Mechanism focus: Stimulates pituitary GHRH receptors; DAC chemistry extends half-life, producing multi-day GH/IGF-1 elevation in human pharmacokinetic studies.
Research Use Cases
- Long-acting GHRH pharmacology
- GH/IGF-1 axis kinetics
- Serum proteome response to sustained GH drive
- Anti-doping detection of GHRH analogs
Use-Case Study Notations
- Case-study notation: clinical pharmacology papers showed prolonged GH and IGF-1 secretion after CJC-1295.
- Case-study notation: once-daily dosing studies quantified enhanced GH/IGF-1 profiles versus shorter GHRH fragments.
- Specify DAC vs non-DAC material in documentation—half-life differs substantially.
Selected Studies (English, PubMed)
Five peer-reviewed sources indexed on PubMed. Links open the PubMed record for verification.
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting GH releasing hormone analog — PubMed 16352683
- Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, enhances GH and IGF-I secretion — PubMed 16822960
- Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes — PubMed 19386527
- Advances in the detection of growth hormone releasing hormone synthetic analogs — PubMed 34665524
- Probing for peptidic drugs (2–10 kDa) in doping control blood samples — PubMed 38716080
Related compounds
Research Use Only. This page is educational and intended for laboratory research context. Products are not for human consumption and are not intended to diagnose, treat, cure, or prevent any disease.